Three oncology studies have cut through the noise this year, and for good reason. In pancreatic cancer, daraxonrasib, a KRAS-targeting drug, nearly doubled median overall survival compared with chemotherapy in previously treated patients.[1] In recurrent or metastatic head and neck cancer, amivantamab, which targets EGFR and MET, led to some complete remissions in heavily pretreated patients.[2] And in melanoma, a Phase III study announced just last week found that adding a personalized mRNA therapy to pembrolizumab, a checkpoint inhibitor, significantly improved both recurrence-free survival and distant metastasis-free survival compared with pembrolizumab alone.[3]
The results are striking, and what unites these studies is that each built on biology that was already well established and found a new way to translate that knowledge into greater clinical benefit. In pancreatic cancer, that meant making actionable a target historically viewed as undruggable; in head and neck cancer, combining two established pathways in a single therapy; and in melanoma, using a personalized mRNA therapy to extend the benefit of checkpoint inhibition.
Together, they illustrate a broader shift in oncology: innovation increasingly comes not only from discovering new biology, but from finding better ways to use, combine, and reinforce the drugs and targets available to us.
From Known Biology to Actionable Biology
Cancer research has spent decades identifying the pathways, mutations, and immune mechanisms that drive disease. Many of oncology’s most important targets, including KRAS, EGFR, HER2, and PD-1/PD-L1, have been studied extensively.
But the challenge is often no longer identifying a target. It is understanding how to make that target therapeutically useful: when it matters, which patients are most likely to benefit, what limits the response, and whether a combination strategy or different treatment can improve the outcome.
The role of KRAS in pancreatic cancer has been known for decades, but the protein was historically considered exceptionally difficult to drug. This is because KRAS binds GDP and GTP (the molecules that switch the protein between its inactive and inactive states) extremely tightly and has a relatively smooth surface with few obvious pockets for small-molecule drugs to engage effectively.[6] The biology was well established; what was missing was an effective way to act on it.
The same principle applies elsewhere. In head and neck cancer, deeper understanding of EGFR, MET, immune interactions, and mechanisms of resistance is informing how established pathways are targeted and combined.[3][4] In immunotherapy, the question is increasingly not only whether checkpoint inhibition works, but how its activity might be extended or reinforced through rational combinations.
In other words, better biological understanding informs patient selection, combination strategies, treatment sequencing, and clinical development, all of which can determine whether a promising mechanism translates into meaningful benefit.[5][3]
Pancreatic Cancer: Making the “Undruggable” Druggable
KRAS mutations are present in the vast majority of pancreatic ductal adenocarcinomas, making the pathway an obvious therapeutic target for decades. The problem was whether it could be inhibited effectively enough to change outcomes.
The breakthrough did not come from identifying a new driver, but from finding a new way to engage one that had resisted conventional drug design.
Daraxonrasib is a multi-selective RAS(ON) inhibitor, meaning it is designed to bind RAS in its active, growth-signaling state across multiple variants. The drug uses a molecular-glue mechanism involving the intracellular protein cyclophilin A to create a binding interface with active RAS, helping overcome the lack of accessible binding pockets that had made the protein so difficult to target. In the Phase III RASolute 302 study, patients with previously treated metastatic pancreatic cancer had a median overall survival of 13.2 months with daraxonrasib, compared with 6.7 months with chemotherapy.[1]
This is a truly meaningful advance in a disease where survival gains have been difficult to achieve for so long; at the same time, a median survival of just over a year makes clear how much unmet need remains.
Head and Neck Cancer: Combining Established Pathways
EGFR is one of the best-established targets in head and neck cancer, but EGFR-directed therapies have produced only modest clinical benefit, in part because tumors can activate alternative signaling pathways that sustain growth and resistance.[7]
Amivantamab was designed around this problem. It is a bispecific antibody, structurally engineered with one binding arm for EGFR and the other for MET, allowing a single molecule to engage both receptors on the tumor cell surface. By doing so, it can block signaling through both pathways and also promote receptor degradation and immune-mediated killing of the tumor cell.
In the Phase Ib/II OrigAMI-4 study, 42% of heavily pretreated patients with recurrent or metastatic head and neck cancer had a confirmed response, including complete remissions in 15%.[2]
The data are still early, but the principle is important: the advance did not come from discovering a new target, but from understanding why an established target was not sufficient on its own, and designing a therapy around that limitation.
Melanoma: Extending the Benefit of Checkpoint Inhibition
Pembrolizumab is already a well-established treatment in melanoma, but checkpoint inhibition does not work equally well in every patient. Its effectiveness depends in part on whether there is a sufficiently active, tumor-specific T-cell response for PD-1 blockade to reinvigorate.
The individualized mRNA therapy intismeran autogene is designed to strengthen that side of the equation. mRNA is a temporary set of genetic instructions that tells cells which protein to make. In intismeran autogene, those instructions are customized to encode neoantigens identified from a patient’s own tumor, so the immune system can learn to recognize those tumor-specific markers and generate a targeted T-cell response. Pembrolizumab then helps keep those T cells active by blocking PD-1 signaling.
Last week, the Phase III INTerpath-001 study reported that the combination significantly improved both recurrence-free survival and distant metastasis-free survival compared with pembrolizumab alone in patients with completely resected stage IIIB-IV melanoma. The magnitude of that benefit has not yet been disclosed.
Those findings build on the earlier Phase IIb KEYNOTE-942 study, which provided the first randomized evidence that the combination could improve outcomes. In the Phase IIb study, adding intismeran autogene to pembrolizumab reduced the risk of recurrence or death by 49% and the risk of distant metastasis by 59% with pembrolizumab alone.[8]
These patients had already undergone surgery to remove all visible melanoma. The role of the mRNA therapy plus pembrolizumab was to reduce the risk that microscopic residual disease left behind that could cause the disease to return or spread. At five years after starting adjuvant treatment, 68.8% of patients who received the combination remained alive without their melanoma recurring, compared with 49.1% of those who received pembrolizumab alone.
The significance of the study is not only that the combination improved outcomes; it shows how an established therapy can potentially be pushed further by pairing it with a second treatment designed around a specific biological limitation.
A Broader Pattern Across Oncology
These studies point to a broader pattern across oncology: progress is increasingly coming from identifying what limits the performance of an established target or therapy, and then designing around that constraint.
Sometimes the barrier is structural, as with KRAS; sometimes it is biological redundancy or resistance, as with EGFR and MET; and sometimes it is the immune context in which the therapy has to work, as with checkpoint inhibition, a cornerstone of modern oncology that includes pembrolizumab, the world’s top-selling drug in 2025.
This same logic is visible in other areas of oncology. Bispecific and trispecific antibodies are being designed to engage more than one target or pathway at once. Antibody-drug conjugates combine established tumor-associated targets with well-characterized cytotoxic mechanisms to concentrate potent payloads more selectively at tumor cells. Radiopharmaceuticals use molecular targeting to concentrate radiation at sites of disease. And rational combinations increasingly pair an established therapy with a second treatment intended to address a specific mechanism of resistance or limitation.
The melanoma findings are particularly relevant to L-DOS47’s development in combination with pembrolizumab. Although the underlying biology is different, both approaches are built around the same therapeutic premise: checkpoint inhibition may be more effective when paired with an intervention that addresses a biological constraint on antitumor immunity. For L-DOS47, that constraint is tumor acidity in and its immunosuppressive effects in the tumor microenvironment.
The common thread is a more deliberate use of biology: identify what is preventing an effective therapy from doing more, then designing an intervention around that limitation.
Bibliography
1. The Conversation. Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival. Science Daily. Published online June 4, 2026. Accessed July 19, 2026. https://www.sciencedaily.com/releases/2026/06/260604044247.htm
2. Advances in pancreatic cancer research. Cancer.gov. May 2, 2019. Accessed July 19, 2026. https://www.cancer.gov/types/pancreatic/research
3. Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA® (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting. https://www.merck.com/news/moderna-and-merck-present-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-in-patients-with-high-risk-stage-iii-iv-melanoma-following-complete-resection-at-the-20/
4. Lee AM, Weaver AN, Acosta P, Harris L, Bowles DW. Review of current and future medical treatments in head and neck squamous cell carcinoma. Cancers (Basel). 2024;16(20):3488. doi:10.3390/cancers16203488
5. Patel SA, Gibson MK, Deal A, et al. A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma. Cancer. 2023;129(21):3381-3389. doi:10.1002/cncr.34930
6. Cracking KRAS, Five anti-cancer KRAS inhibitors, with three different modes of action, are in the clinic. https://www.nature.com/articles/d41573-019-00195-5
7. Emerging EGFR-Targeted Therapy in Head and Neck Cancer: A Review https://pubmed.ncbi.nlm.nih.gov/40996745/
8. Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study https://www.asco.org/abstracts-presentations/259570?_sp=9dd5111b-8951-4ebb-9a14-1440ff5d1a82